A potential explanation for occurrence of infections upon JAK1/2-TKI administration and the overall lack of clinical activity of JAK1/2-TKIs might be that JAK1/2 inhibition reduces abundance and function of NK cells, thereby impairing defense against pathogens and anti-tumor immunity [110,111,112]. Here, JAK1 is linked to neoplasm.